Arrowhead Pharmaceuticals Inc

NASDAQ:ARWR USA Biotechnology
Market Cap
$8.03 Billion
Market Cap Rank
#2246 Global
#1602 in USA
Share Price
$57.57
Change (1 day)
+0.35%
52-Week Range
$9.99 - $73.00
All Time High
$90.47
About

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, a… Read more

Arrowhead Pharmaceuticals Inc (ARWR) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of September 2025: 0.041x

Based on the latest financial reports, Arrowhead Pharmaceuticals Inc (ARWR) has a cash flow conversion efficiency ratio of 0.041x as of September 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($20.49 Million) by net assets ($503.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Arrowhead Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1997–2025)

This chart illustrates how Arrowhead Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Arrowhead Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Arrowhead Pharmaceuticals Inc ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Arrowhead Pharmaceuticals Inc (1997–2025)

The table below shows the annual cash flow conversion efficiency of Arrowhead Pharmaceuticals Inc from 1997 to 2025.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-09-30 $503.42 Million $179.55 Million 0.357x +114.72%
2024-09-30 $191.06 Million $-462.85 Million -2.423x -352.04%
2023-09-30 $287.16 Million $-153.89 Million -0.536x -64.69%
2022-09-30 $418.34 Million $-136.13 Million -0.325x -177.70%
2021-09-30 $408.82 Million $171.22 Million 0.419x +302.75%
2020-09-30 $461.78 Million $-95.39 Million -0.207x -129.13%
2019-09-30 $244.04 Million $173.03 Million 0.709x +243.00%
2018-09-30 $95.24 Million $-47.22 Million -0.496x -67.49%
2017-09-30 $80.87 Million $-23.94 Million -0.296x +56.34%
2016-09-30 $95.02 Million $-64.43 Million -0.678x -13.11%
2015-09-30 $109.62 Million $-65.71 Million -0.599x -180.92%
2014-09-30 $165.99 Million $-35.42 Million -0.213x +71.15%
2013-09-30 $25.73 Million $-19.03 Million -0.740x +57.53%
2012-09-30 $8.81 Million $-15.34 Million -1.741x -305.88%
2011-09-30 $12.56 Million $-5.39 Million -0.429x +54.98%
2010-09-30 $8.08 Million $-7.70 Million -0.953x +69.69%
2009-09-30 $4.86 Million $-15.28 Million -3.145x -40.26%
2008-09-30 $12.30 Million $-27.58 Million -2.242x -148.54%
2007-09-30 $26.46 Million $-23.87 Million -0.902x -92.76%
2006-09-30 $31.61 Million $-14.79 Million -0.468x -44.09%
2005-09-30 $28.02 Million $-9.10 Million -0.325x -57.54%
2004-09-30 $11.23 Million $-2.31 Million -0.206x -85.73%
2003-09-30 $1.42 Million $-157.60K -0.111x -262.64%
2002-09-30 $-1.55 Million $-105.83K 0.068x +8.82%
2001-09-30 $-1.30 Million $-81.81K 0.063x -11.57%
2000-09-30 $-1.13 Million $-80.09K 0.071x +100.61%
1999-09-30 $-996.10K $-35.22K 0.035x +101.32%
1998-09-30 $-2.63 Million $-46.15K 0.018x +1091.72%
1997-09-30 $-2.58 Million $4.56K -0.002x --